|
Topic Name: Bacteria with the mini-genomes for optimized biotechnological uses
Category: Nanobiotechnology
Research persons:
Location: Center Helmholtz de Recherche in Infectiologie (HZI), Inhoffenstrasse 7, D38124 Braunschweig - Tel.: +49 531 6181 4008, fax: +49 531 61 81, Germany
Details
Scientists of the Center Helmholtz de Recherche in Infectiologie (HZI) begin a
European project from development of programmable minibacterias. At the base of
this idea, a report: only some genes of the micro-organisms are used for
biotechnological applications. The researchers of Brunswick thus launch a
project aiming at reducing to the essence the genome of Pseudomonas putida all
while adding to him, n the other hand, a new genetic circuit for the
biotransformation of aromatic compounds chlorinated in elaborate pharmaceutical
molecules.
Through this bacterial reprogramming the researchers intend to prevent the
synthesis of undesirable by-products but also to reduce the temperature
necessary to the biocatalyse. One of the objectives also consists of the
creation of a “flexible” micro-organism being able to be optimized later on
thanks to the directed and accelerated evolution.
Helmholtz center for infection research (HZI) described a bacterial messenger
material as promising tools for more effective and more economical Immune
surgeon: An inoculation with simultaneous gift of this molecule is to make it
possible to in the future already stop exciters with the entrance into the body.
"The most exciter of infection penetrate over the mucous membrane in the body a
“, say Professor Dr. Carlo A. Guzman, Leader the department Vakzinologie the
Helmholtz center for research (HZI). "The entrance to the body with an
inoculation to close, is our research request. “That the group came around
Guzmán now a clear step more near.
"Vaccines need auxiliary materials, so-called Adjuvantien, over well to work to
be able “, describe Dr. Thomas Ebensen, Immunologe at the HZI. Together with its
team Ebensen described a new, much promising auxiliary material now. Adjuvantien
are given together with the vaccine and are obviously RSR: In Europe so far only
two different auxiliary materials have the permission. One actually needs a
whole drawer of full Adjuvantien, since for the different infections also
different immune answers are needed; this reach one by the employment of
differently working Adjuvantien, so the researcher Ebensen.
In one of bacteria produced substance lies now the researcher whole confidence:
"Why signal molecules of bacterial cell cell communication do not use, which
admits to our immune system since more jeher is “, asked oneself Ebensen and
explains: "Bacteria interact during an infection with their environment, thus
also with the human immune cells. Our defense cells recognize the bacterial
signal molecules as danger, when so-called of danger signals react, and. We
examined cyclic mono phosphates, which played a role in bacterial communication
in this context. “
"The substance is highly effective also in very small dosage “, supplements
Ebensens colleague Dr. Kai Schulze. By the employment of efficient Adjuvant like
this inoculation could be offered in the future more economically, since the
concentration of the vaccine can be reduced clearly, say the researchers. Which
for it however is still many more interesting, is the possibility of the better
administration form, about than spray: "Inoculation are accomplished today
primarily by means of syringe “, so the Immunology. That represents a large
problem; the painful "Pieks"reduces the general acceptance of inoculation. Also
in hygienic conditions of the countries of the third world needle inoculation
are a potential danger: The repeated employment of the syringes means a
increased infection risk. "The administration over the mucous membranes,
approximately by a nose spray, is simpler and pain-free “, says Schulze. Besides
so also a protection on the mucous membranes is stimulated and the exciter is
already placed before the penetration, thus before the infection.
Assistance promises the new Adjuvant with a multiplicity of inoculation. At the
HZI it was tested successfully with active substances, which are given against
AIDS, flu virus and hepatitis infections, at mice. "' S continues to go now
however only correctly “, says Ebensen. In its laboratory it will accomplish now
further tests, in order to place surely that mono phosphates become certified as
new auxiliary materials. Into co-operation with the industry and other partners,
like the medical university Hanover, is to go the Adjuvant further developed and
finally into application.
Funded:
This project entitled “Probacty” (Programmable Bacterial Catalysts) is constant
for one duration 3 years by the European Union, to a total value of 1,9 million
euros.
|
